M.Sc. Ana Lucía Calderón Avila is a Nuclear Medicine and Molecular
Imaging resident at the Specialty Hospital, Centro Médico Nacional (CMN SXXI).
She graduated as a Medical Surgeon in 2018 from the Faculty of Medicine, UNAM,
and completed her Master’s in Medical Sciences with Honors at Universidad
Anáhuac, Norte, in 2023. She served as Associate Professor in the Diploma
for Health Area Educators, focusing on research methodology and biostatistics,
from 2019 to 2021 at the Division of Graduate Studies, Faculty of Medicine,
UNAM. She was a research assistant to an Emeritus SNI III researcher at the
National Institute of Genomic Medicine (INMEGEN) from 2018 to 2019. Her
research lines includes the following: Evaluation of myocardial function in patients with
secondary HPT using 99mTc-MIBI SPECT/CT and oxidative stress markers,
2024–present, at Specialty Hospital, CMN SXXI; Evaluation of the molecular
phenotype of breast cancer and bone metastasis patterns using 99mTc-MDP bone
scans, 2023–present, at Specialty Hospital, CMN SXXI; Transcriptome analysis
via NGS in patients with osteosarcoma, 2020–2022, at the National
Rehabilitation Institute; Clinical and genomic characterization of Marfan
syndrome, case series study, 2017–2019, at INMEGEN; and Clinical and molecular
characterization of hypertrophic and dilated cardiomyopathy, either familial or
idiopathic, 2017–2019, at INMEGEN.
M.Sc. Ana Lucía Calderón Avila is a Nuclear Medicine and Molecular
Imaging resident at the Specialty Hospital, Centro Médico Nacional (CMN SXXI).
She graduated as a Medical Surgeon in 2018 from the Faculty of Medicine, UNAM,
and completed her Master’s in Medical Sciences with Honors at Universidad
Anáhuac, Norte, in 2023. She served as Associate Professor in the Diploma
for Health Area Educators, focusing on research methodology and biostatistics,
from 2019 to 2021 at the Division of Graduate Studies, Faculty of Medicine,
UNAM. She was a research assistant to an Emeritus SNI III researcher at the
National Institute of Genomic Medicine (INMEGEN) from 2018 to 2019. Her
research lines includes the following: Evaluation of myocardial function in patients with
secondary HPT using 99mTc-MIBI SPECT/CT and oxidative stress markers,
2024–present, at Specialty Hospital, CMN SXXI; Evaluation of the molecular
phenotype of breast cancer and bone metastasis patterns using 99mTc-MDP bone
scans, 2023–present, at Specialty Hospital, CMN SXXI; Transcriptome analysis
via NGS in patients with osteosarcoma, 2020–2022, at the National
Rehabilitation Institute; Clinical and genomic characterization of Marfan
syndrome, case series study, 2017–2019, at INMEGEN; and Clinical and molecular
characterization of hypertrophic and dilated cardiomyopathy, either familial or
idiopathic, 2017–2019, at INMEGEN.